The effect of N-acetyl cysteine (NAC) on aluminum phosphate poisoning inducing cardiovascular toxicity: a case–control study

Fakhreddin Taghaddosinejad1, Esmaeil Farzaneh2, Mahdi Ghazanfari-Nasrabad3, Nastaran Eizadi-Mood4, Morteza Hajihosseini5 and Omid Mehrpour6*

Abstract

Background: Aluminum phosphate (AlP) is a very effective indoor and outdoor pesticide. We investigated the effects of N-acetyl cysteine (NAC) on the survival time, hemodynamics, and cardiac biochemical parameters at various time intervals in some cases of AlP poisoning.

Methods: This research was a case–control study to evaluate 63 AlP poisoned patients during 2010–2012. Patients with cardiovascular complications of AlP to be treated with intravenous NAC plus conventional treatment were considered as the case group and compared with patients who did not receive NAC. NAC infusion was administered to the case group at 300 mg/kg for 20 h. The data gathered included age, sex, heart rate, Systolic blood pressure (SBP), creatine phosphokinase (CPK), creatine kinase MB (CK-MB), and ECG at the admission time and 12, 18, and 24 h after admission. Analysis of repeated measures was performed to check the variability of parameters over time.

Results: The mean ages in the case and control groups were 26.65 ± 1.06 (19–37 years) and 28.39 ± 1.11 (18–37 years), respectively (P = 0.266). Most of the patients were female (56.5%). CK-MB means were significantly different between the two groups, but no differences between the other variables were observed. Also, CK-MB, CPK, heart rate, and systolic blood pressure means became significantly different over time (0, 12, 18, and 24 h) in both groups (P < 0.001). NAC prevented sharp heart rate fluctuations in AlP patients in the case group. Regarding the outcomes, 17 patients died (10 patients in the control and 7 patients in the case groups). No side-effects of NAC were observed.

Conclusion: Our patients could be managed by the positive role of NAC as the biochemical index of cardiotoxicity was found to elevate in both the case and control groups. Therefore, for the management protocol optimization, NAC evaluation should be done in further cases.

Keywords: Aluminum phosphate, N-acetyl cysteine, Pesticide, Rice tablet

Background

Aluminum phosphate (AlP) is a very effective indoor and outdoor pesticide used in some developing countries (Mehrpour and Singh 2010). In Iran, it is also called rice tablet, which is mainly used to protect rice and grains during storage. The main mechanisms of toxicity are inhibition of cytochrome oxidase c, as well as oxidative stress (Mehrpour et al. 2009, 2014a). After contacting with moisture, AlP releases phosphine gas, which is a lethal poison (Mehrpour et al. 2012). The mortality rates caused by AlP poisoning have been demonstrated as high as 70–100% in various studies (Mehrpour et al. 2012). The main cause of death is a refractory cardiogenic shock (Mehrpour et al. 2011, 2014b). Moreover, other contributing factors include severe hypotension and severe and refractory metabolic acidosis. Since the cardiovascular system is the main target of this poison, various electrocardiographic changes including dysrhythmias may occur by this fatal poisoning.
NAC is an important antioxidant and a cytoprotective agent that replenishes intracellular glutathione. In animal studies, NAC has been shown to have a protective role against cardiovascular complications by protecting heart cells from the oxidative stress induced by phosphine (Shakeri and Mehrpour 2014). Therefore, we investigated the effects of NAC on hemodynamics and cardiac biochemical parameters of AIP poisoning cases at various time intervals as well as during the survival time and compared them with those of the control group.

**Methods**

This research was a case–control study conducted in Baharloo Teaching Hospital, a referral poisoning center in Tehran, Iran during 2010–2012 (Mehrpour and Abdollahi 2012). AIP-poisoned patients were included in the study during the study period. The patients without any symptoms and signs for 12 h and unreliable history and those who died during the first 24 h were excluded from the study. The treatment group (case group) received intravenous NAC plus a conventional treatment. The control group consisted of the patients undergoing only conventional treatment for AIP poisoning. The conventional treatment as our local guideline was administered to both groups included lavage with KMnO4, magnesium sulphate (1 g initially followed by 1 g every 6 h), 10% calcium gluconate (1 g initially followed by 1 g every 6 h), hydrocortisone (200 mg initially followed by 200 mg every 6 h), vitamin C (1000 mg every 12 h via slow intravenous infusion), vitamin E (400 units intramuscularly) NaHCO3 administration for treatment of acidosis (Mehrpour et al. 2008; Oghabian and Mehrpour 2016). NAC infusion was administered to the mentioned group at 300 mg/kg for 20 h. The outcomes were considered for changes in the hemodynamic and cardiac biochemical parameters at the survival time. The patients were also evaluated based on NAC side-effects.

The data gathered included age, sex, heart rate, blood pressure, creatine phosphokinase (CPK), creatine kinase-MB fraction (CK-MB), and ECG at the time of admission and 12, 18, and, 24 h after admission.

The patients were transferred to the Intensive Care Unit (ICU) in case they had an arterial pH less than 7.34 besides cardiovascular symptoms. The data were recorded on a checklist. IBM SPSS 22 was used for the statistical analysis. The data were presented as mean ± SE. Chi Square or Fisher’s exact test was used to compare the two groups. Also, analysis of repeated measures was performed to compare the means between and among the groups at different evaluation times. Figures show the estimated marginal means in each time for both groups. The Estimated Marginal Means are the mean response for each factor, adjusted for any other variables in the model. It means that the Estimated Marginal Means adjust for the covariate by reporting the means of response variable for each level of the factor at the mean value of the covariate. A P value less than 0.05 was considered as significant. An informed consent was obtained from alert patients or their first-degree families or relatives. The study protocol was approved by the ethical committee of Tehran University of Medical Sciences, Tehran, Iran (No. 345).

**Results**

63 Patients with AIP poisoning (caused by oral consumption) were admitted during the study period. The data of 46 patients (23 patients in each group) were analyzed in the study since 17 patients died and were excluded from the study.

The mean ages in the case and control groups were 26.65 ± 1.06 (19–37 years) and 28.39 ± 1.11 years (18–37 years), respectively (P = 0.26). Most of the patients were female (56.5%) (69.6% and 43.5% in the case and control groups, respectively).

The analysis of variance and repeated measures showed that CK-MB means were significantly different between the two groups. However, no significant differences were seen between the groups based on the other variables. Also, CK-MB, CPK, heart rate, and systolic blood pressure means were significantly different over time (0, 12, 18, and 24 h) in the case and control groups. The results revealed that CK-MB means were significantly different after 12, 18, and 24 h of admission in comparison with the admission times in both groups (P < 0.001). Also, there were significant differences between CPK means after 18 and 24 h of admission compared to the admission times in both groups (P < 0.001). Heart rate means were different 18 h after admission compared to the admission time in the control group (P < 0.001). There were significant differences between systolic blood pressure means after admission times compared with the admission time in NAC group (P < 0.001). Different means were obtained between 12 and 18 h after admission and at the admission time in the control group (P < 0.001) (Table 1).

At the time of admission, sinus tachycardia, sinus bradycardia, PVC, QRS widening, ST-elevation MI were observed in 13.0, 8.7, 4.3, 8.7, and 8.7% in the control group respectively. In the case group, sinus tachycardia, sinus bradycardia, PVC, widening of QRS, and ST-elevation MI were discovered in 17.4, 4.3, 4.3, 8.7, and 4.3% of the patients respectively. 12 h after admission, Sinus tachycardia, sinus bradycardia, PVC, widening of QRS, ST-elevation MI, and AF were seen in 17.4, 4.3, 4.3, 8.7, 8.7, and 4.3% of the patients in the case group, respectively. After 18 h, sinus bradycardia, PAC, widening of QRS, ST-elevation MI, VT, and VF were observed in 8.7,
4.3, 4.3, 8.7, 13.0, and 4.3% of the case group, respectively, while 2 patients died. The evaluations after 24 h of admission indicated that sinus tachycardia, sinus bradycardia, PAC, widening of QRS, ST-elevation MI, AF, and VT had occurred in 4.3, 6.3, 4.3, 4.3, 13.0, 4.3, and 4.3% of patients in the case group, respectively. There were no significant differences between the two groups (P value >0.05) (Table 2).

A sudden drop in the heart rates of patients in the control group was observed after 12 and 18 h of admission and then they increased (Fig. 1c). However, using NAC in the case group could prevent sharp fluctuations in the heart rates in AlP patients (Fig. 1e). Moreover, a sudden decrease in the systolic blood pressures of the patients who had received NAC and those of the control group in receiving it in a similar way was observed, while the systolic blood pressures rose sharply to their normal values in the patients who had got NAC for their treatments between 18 and 24 h after admission (Fig. 1d). Regarding the outcomes, 17 patients died [10 patients in the control and 7 patients in the treatment (case) groups]. No side-effects of NAC were observed.

**Discussion**

The generation of superoxide radicals and cellular peroxides is resulted from the inhibitory effects of phosphine on mitochondrial cytochrome-C oxidase. Lipid peroxidation and other oxidant mechanisms subsequently lead to cellular injury. It has been reported that the toxins generated by AlP ingestion leads to a profound circulatory collapse, as the major lethal consequence that directly affects cardiac myocytes and causes adrenal gland

| Table 1 Characteristics of variables in different times in two groups |
|-----------------------------------------------|
| **Variables** | **Group** | **Admission time** | 12 h after admission | 18 h after admission | 24 h after admission |
| | | **Mean (SE)** | **Mean (SE)** | **Mean (SE)** | **Mean (SE)** |
| CK-MB | Control | 20.45 (1.1) | 40.54 (0.9)* | 51.45 (1.7)* | 70.09 (2.6)* |
| | Case (NAC) | 23.69 (1.8) | 40.53 (1.9)* | 52.30 (2.3)* | 68.07 (2.2)* |
| P value | 0.54 | 0.76 | 0.11 | 0.21 |
| CPK | Control | 320.90 (38.6) | 344.90 (23.5) | 726.36 (44.1)* | 1182.81 (114.9)* |
| | Case (NAC) | 358.15 (48.8) | 367.69 (30.2) | 726.69 (68.2)* | 1004.69 (172.5)* |
| P value | 0.82 | 0.51 | 0.34 | 0.31 |
| HR | Control | 80.36 (3.9) | 73.45 (4.7) | 69.63 (5.1)* | 75.81 (4.0) |
| | Case (NAC) | 82.76 (3.1) | 77.69 (6.1) | 78.46 (4.6) | 77.76 (3.7) |
| P value | 0.88 | 0.75 | 0.45 | 0.56 |
| SBP | Control | 106.63 (2.4) | 98.81 (2.5)* | 93.18 (1.2)* | 96.54 (1.2) |
| | Case (NAC) | 100.15 (3.9) | 93.30 (1.5)* | 94.38 (4.1)* | 102.61 (2.7)* |
| P value | 0.23 | 0.94 | 0.55 | 0.32 |

| * Significantly different with admission time in each group |

| Table 2 Distribution of ECG changes in different times |
|-----------------------------------------------|
| **ECG changes** | **Admission time** | 12 h | 18 h | 24 h |
| | **Case (%)** | **Control (%)** | **Case (%)** | **Control (%)** | **Case (%)** | **Control (%)** | **Case (%)** | **Control (%)** |
| No evidence | 56.5 | 60.9 | 39.1 | 47.8 | 34.8 | 43.5 | 26.1 | 30.4 |
| Sinus tachycardia | 13.0 | 17.4 | 17.4 | 17.4 | 8.7 | 8.7 | 4.3 | 4.3 |
| Sinus bradycardia | 8.7 | 4.3 | 4.3 | NAD | NAD | NAD | NAD | NAD |
| PVC | 4.3 | 4.3 | 4.3 | NAD | NAD | NAD | NAD | NAD |
| PAC | NAD | NAD | NAD | NAD | 4.3 | 4.3 | 4.3 | NAD |
| QRS widening | 8.7 | 8.7 | 8.7 | 8.7 | 4.3 | NAD | 4.3 | NAD |
| ST. elevation | 8.7 | 4.3 | 8.7 | NAD | 8.7 | NAD | 13.0 | NAD |
| A.F. | NAD | NAD | 4.3 | NAD | NAD | NAD | 4.3 | NAD |
| V.T | NAD | NAD | NAD | NAD | 13.0 | 21.7 | 4.3 | NAD |
| V.F. | NAD | NAD | NAD | NAD | 4.3 | 4.3 | NAD | 4.3 |

| NAD no abnormality detected |
damage and fluid loss (Mehrpour et al. 2009, 2012, 2014a; Mehrpour and Singh 2010).

So far, supportive therapy is the main treatment for such patients since there is no specific antidote to stop AIP poisoning (Mostafazadeh and Farzaneh 2012).

Treatment of cardiogenic shock as one of the main causes of death in AIP poisoning may reduce the relevant mortality (Mehrpour et al. 2011, 2012, 2014b). Intra-aortic Balloon Pump (IABP) (Mehrpour et al. 2014b), glucagon (Oghabian and Mehrpour 2016), and digoxin (Mehrpour et al. 2011) are used to manage cardiogenic shock in some treatments. IABP has been shown to be another excellent treatment for AIP poisoning by previous studies. Moreover, in severe cases of AIP poisoning, IABP addition to the treatment protocol has been strongly recommended by some researchers besides using Extracorporeal Membrane Oxygenation (ECMO) (Hassanian-Moghaddam et al. 2016).

Acidosis can be reversed through improved uptake of myocyte carbohydrate (Hassanian-Moghaddam and Zamani 2016). Also, the use of hyperinsulinemia/euglycemia (HIE) as another useful treatment improves inotropy and peripheral vascular resistance (Hassanian-Moghaddam and Zamani 2016).
Furthermore, coconut oil, which is believed to inhibit phosphine gas release from AIP due to the physicochemical properties of aluminium phosphide and its non-miscibility with fat (Shadnia et al. 2005) has been suggested for gastric lavage in acute AIP poisoning by some researchers (Shadnia et al. 2005).

Oxidative stress is one of the main mechanisms of AIP to induce toxicity (Mehrpour et al. 2012, 2014a). Vitamins C and E and N-acetylcysteine (Oghabian and Mehrpour 2016) as antioxidant agents have been shown by the previous studies to have significant benefits in AIP poisoning management. Recently, via a combination of the mentioned antioxidant agents and intravenous glucagon and digoxin, AIP poisoning has been successfully reported to be treated by Oghabian and Mehrpour (2016). Meanwhile, that oxidative stress is believed by Abdollahi et al. (2004) to be one of the main mechanisms of AIP toxicity, which is somewhat similar to those of organophosphate (OP) compounds (Abdollahi et al. 2004).

Also, glutathione as a main antioxidant defense is reduced by AIP. Actually, changes in glucose metabolism were associated with AIP and OP that cause a toxic stress in a similar way (Rahimi and Abdollahi 2007; Nath et al. 2011). Antioxidant agents seem to usefully reduce the toxicity. Cellular glutathione and magnesium have been shown to be replenished in rats (Hsu et al. 2000, 2002) and humans (Chugh et al. 1997) with the help of N-acetylcysteine, which has antioxidant properties through different studies. Myocardial oxidative injury in rats exposed to AIP has been shown to be reduced by N-acetylcysteine, while increasing their survival times (Bogle et al. 2006).

In this study, N-acetylcysteine was examined for reducing oxidative stress and AIP causing cardiotoxicity. In these patients, cardiogenic shock and cardiotoxicity are the most important causes of mortality. Various types of cardiac dysrhythmia, such as VT (17.4%), sinus tachycardia (10.87%), VF (8.7%), ST elevation (8.7%), widening of QRS (8.7%), sinus bradycardia (6.5%), PAC (6.5%), PVC (2.2%), and AF (2.2%) were discovered in this research. No significant difference was found between the groups though the case group was associated with a lower rate of dysrhythmia. In cases of AIP poisoning various types of cardiac events or dysrhythmia may be happened such as sinus tachycardia, VF, VT, ST elevation, widening of QRS, sinus bradycardia, PAC, PVC, and AF. Of them VF and VT seems to be terminal cardiac dysrhythmia before death (Mehrpour et al. 2012).

In the previous studies, ECG changes including ST-T changes, AV conduction disturbances, bundle branch blocks, supraventricular and ventricular tachycardia, and atrial fibrillation have been precisely investigated (Jain Sm et al. 1985; Chugh et al. 1989, 1991; Soltaninejad et al. 2012). Therefore, the outcome of ECG changes is influenced by the changes in CPK and CK-MB levels at hospital admission. Also, CPK and CK-MB repeated measurements were used in this study. The four cardiac indices of CPK, CK-MB, SBP, and heart rate were evaluated and compared in the control and case groups. Myocardial damage during AIP poisoning was confirmed by CPK and CK-MB enhancements in both groups with the passage of time. However, lower rates of CPK and CK-MB, especially after 12 and 18 h, respectively, and bradycardia deceleration in SBP over time were revealed in the case group receiving NAC. AIP poisoning treatment with antioxidants, especially NAC in our study was the same result obtained by other investigations (Duenas et al. 1999). Meanwhile, significantly lower rates of intubation,
ventilation, and mortality and shorter duration of hospitalization were found in AIP-poisoned patients treated with NAC compared to the controls in the previous study (Tehrani et al. 2013).

Some limitations in our study included exclusion of patients who died within the first 24 h of admission and inability to analyze the different variables between the two groups based on alive or dead patients due to the small number of dead patients in both groups. Nonetheless, reduced rate of mortality in AIP patients was clearly found to be resulted from NAC effect on some cardiac variables, such as heart rate and SBP in this study.

Conclusion
Our patients could be managed by the positive role of NAC as the biochemical index of cardiotoxicity was found to elevate in both the case and control groups. Therefore, for the management protocol optimization, NAC evaluation should be done in further cases.

Abbreviations
Alp: aluminum phosphide; NAC: N-acetyl cysteine; CK-MB: creatine kinase MB; ECG: electrocardiography; SBP: systolic blood pressure; CPK: creatine phosphokinase; ICU: Intensive Care Unit; PVC: premature ventricular contraction; MI: myocardial infarction; AF: atrial fibrillation; VT: ventricular tachycardia; VF: ventricular fibrillation; HIE: Hyperinsulinemia/euglycemia; OP: organophosphate.

Authors’ contributions
FT participated in the study design and drafted the manuscript. MG and EF participated in the data collection. NE and MH participated in the design of the study and performed the statistical analysis. OM conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Forensic Medicine, Tehran University of Medical Sciences, Tehran, Iran. 2 Department of Forensic Medicine and Toxicology, Ardabil University of Medical Sciences, Ardabil, Iran. 3 Legal Medicine Research Center, Legal Medicine Organization, Baheerat Cross, Taleghani Avenue, Tehran 1114795113, Iran. 4 Isfahan Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. 5 Birjand CardioVascular Diseases Research Center, Birjand University of Medical Sciences, Moalem Avenue, Birjand 9713643138, Iran. 6 Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Moalem Avenue, Birjand 9713643138, Iran.

Acknowledgements
This study was result of specialty thesis of Mahdi Ghanzafarni-Nasrabadi which supported by the Deputy of Research and Technology of Tehran University of Medical Sciences.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
Data will not be shared because we do not have a reliable university host domain for availability of data.

Ethics approval and consent to participate
An informed consent was obtained from alert patients or their first-degree families or relatives. The study protocol was approved by the ethical committee of Tehran University of Medical Sciences, Tehran, Iran (No. 345).

Funding
This study was supported by the Deputy of Research and Technology of Tehran University of Medical Sciences had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.

Received: 16 June 2016 Accepted: 1 November 2016
Published online: 10 November 2016

References
Abdollahi M, Ranjarb A, Shadnia S et al (2004) Pesticides and oxidative stress: a review. Med Sci Monit 10:RA141–RA147
Akkaoui M, Achour S, Abidi K et al (2007) Reversible myocardial injury associated with aluminum phosphate poisoning. Clin Toxicol 45:728–731
Anand R, Kumari P, Kaushal A et al (2012) Effect of acute aluminum phosphate exposure on rats—a biochemical and histological correlation. Toxicol Lett 215:62–69
Bogle R, Theron P, Brooks P et al (2006) Aluminium phosphate poisoning. Emerg Med J 23:e03-e
Chugh S, JaggaI K, Ram S et al (1989) Hypomagnesaemic atrial fibrillation in a case of aluminium phosphate poisoning. J Assoc Physicians India 37:548–549
Chugh SNCK, Ram S, Malhotra KC (1991) Electrocardiographic abnormalities in aluminium phosphate poisoning with special reference to its incidence, pathogenesis, mortality and histopathology. J Indian Med Assoc 89:32–35
Chugh S, Kolley T, Kakkar R et al (1997) A critical evaluation of anti-oxidant effect of intravenous magnesium in acute aluminium phosphate poisoning. Magnes Res 10:225–230
Duenas A, Perez-Castillon J, Cobos M et al (1999) Treatment of the cardiovascular manifestations of phosphine poisoning with trimetazidine, a new antiischemic drug. Ann J Emerg Med 17:219–220
Hassanian-Moghaddam H, Zamani N (2016) Therapeutic role of hyperinsulinemia/euglycemia in aluminium phosphate poisoning. Medicine 95:e4349
Hassanian-Moghaddam H, Zamani N, Rahimi M et al (2016) Successful treatment of aluminium phosphate poisoning by extracorporeal membrane oxygenation. Basic Clin Pharmacol Toxicol 118:243–246
Hsu C-H, Han B-C, Liu M-Y et al (2000) Phosphine-induced oxidative damage in rats: attenuation by melatonin. Free Radic Biol Med 28:636–642
Hsu C-H, Chi B-C, Liu M-Y et al (2002) Phosphine-induced oxidative damage in rats: role of glutathione. Toxicology 179:1–8
Jain Sm BA, Sepaha GC, Sanghavi VC, Raman PG (1985) Electrocardiographic changes in aluminium phosphate poisoning. J Assoc Phys India 33:406–409
Karami-Mohajeri S, Jafari A, Abdollahi M (2013) Comprehensive review of the mechanistic approach and related therapies to cardiovascular effects of aluminium phosphate. Int J Pharmacol 94:93–500
Kaushik RM, Kaushik R, Mahajan SK (2007) Subendocardial infarction in a young survivor of aluminium phosphate poisoning. Hum Exp Toxicol 26:457–460
Mehrpour O, Abdollahi M (2012) Poison treatment centers in Iran. Hum Exp Toxicol 31:303–304
Mehrpour O, Singh S (2010) Rice tablet poisoning: a major concern in Iranian population. Hum Exp Toxicol 29:701
Mehrpour O, Alfred S, Shadnia S et al (2008) Hyperglycemia in acute aluminum phosphate poisoning as a potential prognostic factor. Hum Exp Toxicol 27:591–595
Mehrpour O, Keyler D, Shadnia S (2009) Comment on Aluminium and zinc phosphate poisoning. Clin Toxicol 47:838–839
Mehrpour O, Farzaneh E, Abdollahi M (2011) Successful treatment of aluminum phosphate poisoning with digoxin: a case report and review of literature. Int J Pharmacol 7:761–764
Mehrpour O, Jafarzadeh M, Abdollahi M (2012) A systematic review of aluminum phosphate poisoning. Arch Ital Hyg Toxicol 63:61–73
Mehrpour O, Abdollahi M, Sharifi MD (2014a) Oxidative stress and hyperglycemia in aluminum phosphate poisoning. J Res Med Sci 19
Mehrpour O, Amouzeshi A, Dadpour B et al (2014b) Successful treatment of cardiogenic shock with an intraaortic balloon pump following aluminum phosphate poisoning. Arch Ital Hyg Toxicol 65:121–127.
Mostafazadeh B, Farzaneh E (2012) A novel protocol for gastric lavage in patients with aluminum phosphide poisoning: a double-blind study. Acta Med Iran 50:530–534
Nath NS, Bhattacharya I, Tuck AG et al (2011) Mechanisms of phosphine toxicity. J Toxicol 2011
Nayyar S, Nair M (2009) Brugada pattern in toxic myocarditis due to severe aluminum phosphide poisoning. Pacing Clin Electrophysiol 32:e16–e17
Oghabian Z, Mehrpour O (2016) Treatment of aluminium phosphate poisoning with a combination of intravenous glucagon, digoxin and antioxidant agents. Sultan Qaboos Univ Med J 16:e352–35
Rahimi R, Abdollahi M (2007) A review on the mechanisms involved in hyperglycemia induced by organophosphorus pesticides. Pestic Biochem Physiol 88:115–121
Shadnia S, Rahimi M, Pajoumand A et al (2005) Successful treatment of acute aluminium phosphide poisoning: possible benefit of coconut oil. Hum Exp Toxicol 24:215–218
Shah V, Baxi S, Vyas T (2009) Severe myocardial depression in a patient with aluminium phosphide poisoning: a clinical, electrocardiographical and histopathological correlation. Indian J Crit Care Med 13:41
Shakeri S, Mehrpour O (2014) Aluminum phosphide poisoning in animals. Int J Med Toxicol Forensic Med 5:81–97
Soltaninejad K, Shadnia S, Ziyapour B et al (2009) Aluminum phosphide intoxication mimicking ischemic heart disease led to unjustified treatment with streptokinase. Clin Toxicol 47:908–909
Soltaninejad K, Beyranvand M-R, Momenzadeh S-A et al (2012) Electrocardiographic findings and cardiac manifestations in acute aluminum phosphide poisoning. J Forensic Leg Med 19:291–293
Tehtani H, Halvaei Z, Shadnia S et al (2013) Protective effects of N-acetyl-cysteine on aluminum phosphide-induced oxidative stress in acute human poisoning. Clin Toxicol 51:23–28